69 results about "Polyribonucleotides" patented technology

The present disclosure relates, generally, to methods for producing, purifying, and using circular RNA from a prokaryotic system.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

The present disclosure provides circular polyribonucleotides including a sequence including: a circularization element; a first spacer; an internal ribosome entry site (IRES) sequence; a sequence encoding a polypeptide; and a second spacer, where the sequence encoding the polypeptide has been codon-optimized to reduce the number of uracil ribonucleotides and / or reduce or remove TLR7- and TLR8-recognition motifs, and kits and compositions thereof. The present disclosure also provides methods of treating subjects in need thereof with the circular polyribonucleotides and compositions described herein.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

This disclosure relates to lipid compounds and lipid nanoparticles (LNPs) prepared therefrom that are particularly effective in delivery of circular polyribonucleotides. Methods of use of the lipid compounds and LNPs, e.g., for circular RNA delivery, are also provided.

The present disclosure provides pharmaceutical compositions for delivery of orthopoxvirus antigens (e.g., mpox, variola, borealpox, ectromelia, cowpox, volepox, modified vaccinia virus Ankara, or vaccinia) and related technologies (e.g., components thereof and / or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more mpox antigens, fragments, or fusions thereof.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for the delivery of malaria protein antigens. Among other things, the present disclosure provides polyribonucleotides encoding malaria protein antigens.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for delivery of anti-HIV antibody agents. The present disclosure provides, among other things, polyribonucleotides encoding immunoglobulin chains of anti-HIV antibody agents. The present disclosure recognizes that HIV mutates rapidly. The highly mutating nature of HIV virions allows them to escape host immune and / or therapeutic pressures.

In various aspects and embodiments the invention provides a method of treating an autoimmune or autoinflammatory dermatological condition in a subject in need thereof, the method comprising: performing RNA in situ hybridization on a tissue sample obtained from the patient with at least one probe that binds to a polyribonucleotide encoding at least one cytokine to determine a level of the at least one cytokine; comparing the level of the at least one cytokine to a normal control; determining that the level of the at least one cytokine deviates from the normal control; and providing treatment for the dermatological condition to the subject.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium circumsporozoite protein (CSP) antigens and related techniques (e.g., components thereof and / or methods related thereto). The present disclosure provides, among other things, a polyribonucleotide comprising a coding sequence encoding a full-length Plasmodium CSP polypeptide. In some embodiments, the full-length Plasmodium CSP polypeptide comprises a Plasmodium CSP N-terminal domain, and the coding sequence of the polyribonucleotide encoding the full-length Plasmodium CSP polypeptide has a particular nucleotide content as provided herein.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The disclosure provides compositions and methods comprising circular polyribonucleotides comprising a sequence encoding a coronavirus immunogen, and compositions and methods comprising linear polyribonucleotides comprising a sequence encoding one or more coronavirus immunogens. Compositions and methods are provided that are related to generating polyclonal antibodies, for example, using the disclosed circular polyribonucleotides or the disclosed linear polyribonucleotides.